(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 September 2024 (26.09.2024)

WIPO | PCT

(10) International Publication Number
WO 2024/197151 A2

(51) International Patent Classification:
*A61K 47/68* (2017.01) *C07K 16/00* (2006.01)

(21) International Application Number:
PCT/US2024/020929

(22) International Filing Date:
21 March 2024 (21.03.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/453,929 22 March 2023 (22.03.2023) US

(71) Applicant: **SALUBRIS BIOTHERAPEUTICS, INC.** [US/US]; 45 West Watkins Mill Road, Suite E, Gaithersburg, Maryland 20878 (US).

(72) Inventors: **MURPHY, Samuel L.**; c/o Salubris Biotherapeutics, Inc., 45 West Watkins Mill Road, Suite E, Gaithersburg, Maryland 20878 (US). **MCNALLY, Jonathan P.**; c/o Salubris Biotherapeutics, Inc., 45 West Watkins Mill Road, Suite E, Gaithersburg, Maryland 20878 (US). **BEZABEH, Binyam Z.**; c/o Salubris Biotherapeutics, Inc., 45 West Watkins Mill Road, Suite E, Gaithersburg, Maryland 20878 (US). **LI, John**; c/o Salubris Biotherapeutics, Inc., 45 West Watkins Mill Road, Suite E, Gaithersburg, Maryland 20878 (US).

(74) Agent: **PAVAO, Matthew** et al.; Cooley LLP, ATTN: IP Docketing Department, 1299 Pennsylvania Avenue NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: ANTI-5T4 ANTIGEN BINDING DOMAINS, ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF

(57) Abstract: The disclosure provides anti-5T4 antigen binding domains, which can be incorporated into antibodies and receptors, including bispecific anti-5T4 antibodies, biparatopic anti-5T4 antibodies, and antibody-drug conjugates of same comprising a first antigen binding domain that specifically binds to a first 5T4 epitope, a second antibody antigen binding domain that specifically binds to a second 5T4 epitope that is not the same as the first 5T4 epitope, wherein the first antigen binding domain is operably linked to the second antigen binding domain, and a chemotherapeutic agent. The disclosure further provides methods of using same for the treatment of cancer.




FIG. 1A




FIG. 1B

WO 2024/197151 A2

*[Continued on next page]*

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*